Semaglutide confirms its position in cardiovascular prevention in the SELECT study

Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. <http://dx.doi.org/10.1056/NEJMoa2307563>. Supplementary Appendix (nejmoa2307563_appendix.pdf).

Butler J, Schuyler Jones W, Udell JA et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med 2024; 390(16): 1455–1466. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2314051>.

Lincoff AM, Ryan DH, Esbjerg S et al. Semaglutide and Cardiovascular Outcomes. Reply. N Engl J Med 2024; 390(8): 768–769. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc2400414>.

Volpe M, Borghi C, Cameli M et al. How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion. Int J Cardiol 2023; 381: 101–104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2023.03.054>.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. Dostupné z WWW: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or> [08/03/2024].

Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Press release 08/03/2024. Dostupné z WWW: <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167030>.

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Press release 08/08/2023. Dostupné z WWW: <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166301>.

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack. Eli Lilly and Company. Dostupné z WWW: <https://investor.lilly.com/news-releases/news-release-details/us-fda-grants-fast-track-designation-jardiancer-empagliflozin>.

EMPACT-MI: Is Preventing HF After Heart Attack the Next Frontier for SGLT2 Inhibitors? Dostupné WWW: <https://www.ajmc.com/view/empact-mi-is-preventing-hf-after-heart-attack-the-next-frontier-for-sglt2-inhibitors->.

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI. Conference News ACC 2024. Dostupné z WWW: <https://www.tctmd.com/news/early-empagliflozin-doesnt-curb-hf-hospitalizations-deaths-post-mi-empact-mi>.

Vorlíčková P, Mayer O Jr, Bruthans J et kal. Změny v adherenci k doporučené cílové hodnotě LDL cholesterolu mezi lety 2006 a 2017 u českých pacientů s chronickou ischemickou chorobou srdeční. Cor Vasa 2019; 61(1): 20–27. Dostupné z WWW: https://e-coretvasa.cz/pdfs/cor/2019/01/03.pdf>.

Ryan DH, Deanfield JE, Jacob S et al. Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes. Cardiovasc Endocrinol Metab 2023; 12(1): e0279. Dostupné z DOI: <http://dx.doi.org/10.1097/XCE.0000000000000279>.

Semaglutide ‘A New Pathway’ to CVD Risk Reduction: SELECT. Dostupné z WWW: <https://www.medscape.com/viewarticle/998373?scode=msp&st=fpf&socialSite=google&icd=login_success_gg_match_fpf&form=fpf>.

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics. Conference News AHA 2023. Dostupné z WWW: <https://www.tctmd.com/news/full-select-results-affirm-cv-risk-reduction-semaglutide-nondiabetics>.

EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death. ACC News Story. [06–04–2024]. Dostupné z WWW: <https://www.acc.org/Latest-in-Cardiology/Articles/2024/04/02/17/02/sat-930am-empact-mi-acc-2024>.

James S, Erlinge D, Storey RF et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid 2024; 3(2): EVIDoa2300286. Dostupné z DOI: <http://dx.doi.org/10.1056/EVIDoa2300286>.